[go: up one dir, main page]

DE69927041D1 - ZERO IGF FOR CANCER TREATMENT - Google Patents

ZERO IGF FOR CANCER TREATMENT

Info

Publication number
DE69927041D1
DE69927041D1 DE69927041T DE69927041T DE69927041D1 DE 69927041 D1 DE69927041 D1 DE 69927041D1 DE 69927041 T DE69927041 T DE 69927041T DE 69927041 T DE69927041 T DE 69927041T DE 69927041 D1 DE69927041 D1 DE 69927041D1
Authority
DE
Germany
Prior art keywords
igf
zero
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927041T
Other languages
German (de)
Other versions
DE69927041T2 (en
Inventor
Desmond Mascarenhas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/399,120 external-priority patent/US7288516B1/en
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of DE69927041D1 publication Critical patent/DE69927041D1/en
Application granted granted Critical
Publication of DE69927041T2 publication Critical patent/DE69927041T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New methods for the treatment of cancer are provided. Null IGF(IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer.
DE69927041T 1998-10-02 1999-09-29 ZERO IGF FOR CANCER TREATMENT Expired - Fee Related DE69927041T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10274798P 1998-10-02 1998-10-02
US09/399,120 US7288516B1 (en) 1999-09-20 1999-09-20 Null IGF for the treatment of cancer
PCT/US1999/022681 WO2000020023A2 (en) 1998-10-02 1999-09-29 Null igf for the treatment of cancer

Publications (2)

Publication Number Publication Date
DE69927041D1 true DE69927041D1 (en) 2005-10-06
DE69927041T2 DE69927041T2 (en) 2006-06-14

Family

ID=26799690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927041T Expired - Fee Related DE69927041T2 (en) 1998-10-02 1999-09-29 ZERO IGF FOR CANCER TREATMENT

Country Status (8)

Country Link
EP (1) EP1117424B1 (en)
JP (1) JP2003522110A (en)
AT (1) ATE303159T1 (en)
AU (1) AU767141B2 (en)
CA (1) CA2345353C (en)
DE (1) DE69927041T2 (en)
HK (1) HK1040906B (en)
WO (1) WO2000020023A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3971108B2 (en) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド Insulin-like growth factor (IGF) I mutants
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US20030035788A1 (en) 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
AU1439095A (en) * 1993-12-15 1995-07-03 Thomas Jefferson University Igf-1 analogs
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3

Also Published As

Publication number Publication date
EP1117424A2 (en) 2001-07-25
WO2000020023A3 (en) 2000-07-06
WO2000020023A2 (en) 2000-04-13
ATE303159T1 (en) 2005-09-15
HK1040906B (en) 2005-12-09
AU767141B2 (en) 2003-10-30
DE69927041T2 (en) 2006-06-14
HK1040906A1 (en) 2002-06-28
AU6277899A (en) 2000-04-26
CA2345353A1 (en) 2000-04-13
JP2003522110A (en) 2003-07-22
EP1117424B1 (en) 2005-08-31
CA2345353C (en) 2009-07-07

Similar Documents

Publication Publication Date Title
IL254264A (en) Dosages for treatment with anti-erbb2 antibodies
DK1189629T3 (en) Peptide YY (PYY) for the treatment of glucose metabolism
ATE382364T1 (en) PEPTIDE DERIVED FROM IGF BINDING PROTEIN
PT1157041E (en) ANTIBODIES FOR CANCER THERAPY AND DIAGNOSIS
NO20016007D0 (en) Recombinant anti-CD40 antibody and uses thereof
BR9913645A (en) Combined therapies for B-cell lymphomas comprising administration of anti-cd20 antibody
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
BR9714523A (en) Treatment of lupus nephritis with anti-cd40l compounds
WO1999057117A3 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
CY1108489T1 (en) MANUFACTURE OF CATALOGS
PH12012502440A1 (en) Antibodies to opgl
TR200000755T2 (en) Treatment of anti-oppositional disorder.
NO20020779D0 (en) Methods, preparations and kits to promote healing of central nervous system damage
IL146125A0 (en) Novel quinones as disease therapies
HUP9901908A2 (en) P16 expression constructs and their application in cancer therapy
ATE303159T1 (en) ZERO IGF FOR CANCER TREATMENT
NO20015932L (en) Procedures for treating diabetes
WO2004083236A3 (en) Cancer treatment using proanp peptides
DE69520430D1 (en) META SUBSTITUTED ARYLALKYLAMINE AND THERAPEUTIC AND DIAGNOSTIC USE THEREOF
EA200500934A1 (en) Compounds modulating the activity of the kinase protein of multiple lines and methods for the treatment of neurodegenerative and inflammatory diseases
PT951553E (en) ADENOVIRUS E4 PROTEINS FOR CELL DEATHS
ATE223721T1 (en) EDELFOSINE FOR THE TREATMENT OF BRAIN TUMORS
NO20020329D0 (en) Anti-tumor antibodies, proteins and uses thereof
AU2346301A (en) Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases
MD743F1 (en) Remedy for immunity system and hormonal homeostasis normalization

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee